News

New Report Highlights Risks of U.S. Drug Reimportation

New Report Highlights Risks of U.S. Drug Reimportation

While the reimportation of drugs into the U.S. from abroad is a popular topic among politicians and advocates looking for ways to reduce domestic healthcare costs, the research arm of the Healthcare Distribution Alliance has released a new report highlighting some little-discussed costs and risks associated with reimportation. Yourway is no stranger to logistical challenges and is monitoring this issue.

Back to Index
Media

Upcoming Event

10th Annual SCM Pharma Summit

September 24-25, 2019
Mumbai, India

Media

Articles

Keys to Successful Storage, Management and Transport of Biological Materials